on Eckert & Ziegler Strahlen- Und Medizintechnik AG (isin : DE0005659700)
Eckert & Ziegler Partner with AtomVie on Lutetium-177 Supply
On March 20, 2025, Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. announced a global supply agreement for Lutetium-177. Eckert & Ziegler will supply its high-quality Lutetium-177 chloride, Theralugand®, to support AtomVie’s contract development and manufacturing operations for radiopharmaceuticals. This collaboration spans early and late-stage development, facilitating global programs for AtomVie.
The agreement allows AtomVie to secure Theralugand® for developing Lutetium-177 based radiopharmaceuticals. This flexibility addresses pharmaceutical needs at different stages of development and meets global regulatory standards. Eckert & Ziegler's CEO, Dr. Harald Hasselmann, emphasized the importance of their contribution to nuclear medicine advances.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news